Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-26 · accession 0001968202-24-000074 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-26 | REGN | Bassler Bonnie L | Dir | M - OptEx | $391.92 | +854 | 2,236 | +62% | +$334.7K |
| D | 2024-02-26 | 2024-02-26 | REGN | Bassler Bonnie L | Dir | S - Sale+OE | $979.25 | -854 | 1,382 | -38% | -$836.3K |
| D | 2024-02-26 | 2024-02-26 | REGN | Bassler Bonnie L | Dir | M - OptEx | $0.00 | -854 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-26 | M | A | 854 | $391.92 | 2,236 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-26 | S | D | 854 | $979.25 | 1,382 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-26 | M | D | 854 | $0.00 | 0 | D | $391.92 · — to 2026-09-09 | 854 Common Stock | (F1) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |